Core Viewpoint - Class actions have been initiated for investors of Hims & Hers Health, Inc. and Sarepta Therapeutics, Inc. due to alleged misleading statements and undisclosed risks related to their business operations and products [1][4]. Hims & Hers Health, Inc. (NYSE: HIMS) - The class period for Hims & Hers is from April 29, 2025, to June 23, 2025, with a lead plaintiff deadline of August 25, 2025 [2]. - Allegations include that Hims engaged in deceptive promotion of illegitimate versions of Wegovy, risking patient safety and jeopardizing its collaboration with Novo Nordisk [2][3]. - Defendants are accused of making materially misleading statements regarding the safety and availability of Wegovy for Hims subscribers, which lacked a reasonable basis [2][3]. Sarepta Therapeutics, Inc. (NASDAQ: SRPT) - The class period for Sarepta is from June 22, 2023, to June 24, 2025, also with a lead plaintiff deadline of August 25, 2025 [4]. - Sarepta is alleged to have misled investors about the safety and revenue outlook of its gene therapy ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [4]. - Significant safety risks associated with ELEVIDYS were not disclosed, leading to adverse events that prompted the company to halt clinical trials and attract regulatory scrutiny [4][5]. - Following reports of patient deaths related to ELEVIDYS, Sarepta's stock experienced significant declines, including a drop of $27.81 per share (27.44%) on March 18, 2025, and a further decline of $15.24 per share (42.12%) on June 15, 2025 [5][6].

Exhibit 99.1 Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label CAMBRIDGE, Mass., July 16, 2025 (BUSINESS WIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan designed to prioritize high-value, high impact programs, meet its 2027 financial obligations, and support its long-term financial v ...

Sarepta is cutting more than one-third of its workforce and will add a black box warning label to its gene therapy for a fatal muscle disorder after two patient deaths raised doubts about the future of the company https://t.co/FHYwnWd7ml ...

Core Viewpoint - A securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety and efficacy of its gene therapy treatment, ELEVIDYS, during the class period from June 22, 2023, to June 24, 2025 [1][2]. Allegations Against Defendants - The complaint claims that Sarepta made false or misleading statements and failed to disclose significant safety risks associated with ELEVIDYS [2]. - It is alleged that the trial protocols for ELEVIDYS did not adequately detect severe side effects, leading to potential regulatory scrutiny and halting of recruitment and dosing in trials [2]. - The severity of adverse events from ELEVIDYS treatment is said to have materially misled investors regarding the therapy's approval prospects [2]. Lead Plaintiff Process - Investors in Sarepta have until August 25, 2025, to seek appointment as a lead plaintiff, representing the class in the litigation [3]. - The lead plaintiff is typically the investor or group of investors with the largest financial interest and who are representative of the class [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/sarepta-loss-submission-form/?id=156709&from=3 CLASS PERIOD: June 22, 2 ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sarepta Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the safety of its drug ELEVIDYS [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Sarepta between June 22, 2023, and June 24, 2025, to discuss their legal rights [1]. - There is an August 25, 2025, deadline for investors to seek the role of lead plaintiff in a federal securities class action against Sarepta [2]. - The complaint alleges that Sarepta and its executives made false statements regarding the safety of ELEVIDYS, which posed significant risks to patients [4]. Group 2: Stock Price Impact - Following a safety update on March 18, 2025, Sarepta's stock price fell by $27.81 per share, or 27.44%, closing at $73.54 [5]. - On April 4, 2025, after disclosing regulatory scrutiny, the stock price dropped by $4.18 per share, or 7.13%, closing at $54.43 [6]. - A second patient death reported on June 15, 2025, led to a significant stock price decline of $15.24 per share, or 42.12%, closing at $20.91 [8]. - Following an FDA Safety Communication on June 24, 2025, the stock price fell by $1.52 per share, or 8.01%, closing at $17.46 [9]. Group 3: Company Background - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in multiple states [3].

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/sarepta-lawsuit-submi ...

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. concerning allegations of securities fraud and unlawful business practices related to its drug ELEVIDYS [1][2]. Group 1: Lawsuit Details - The lawsuit involves claims that Sarepta and certain officers/directors engaged in securities fraud or other unlawful practices [2]. - Investors who purchased Sarepta securities during the Class Period have until August 25, 2025, to request appointment as Lead Plaintiff [2]. Group 2: Impact of ELEVIDYS - On March 18, 2025, Sarepta reported the death of a patient with Duchenne muscular dystrophy after treatment with ELEVIDYS, leading to a stock price drop of $27.81 (27.44%) to $73.54 [4]. - Following a request from EU authorities for a review of the death, Sarepta halted recruitment and dosing in some clinical studies, resulting in a further stock decline of $4.18 (7.13%) to $54.43 on April 4, 2025 [5]. - A second fatality from acute liver failure was reported on June 15, 2025, prompting Sarepta to halt its clinical trial and suspend distribution of ELEVIDYS, causing a significant stock drop of $15.24 (42.12%) to $20.94 [6]. - The FDA issued a Safety Communication on June 24, 2025, regarding the investigation of acute liver failure risks associated with ELEVIDYS, leading to a stock price decrease of $1.52 (8.01%) to $17.46 [7].

Core Points - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the company's gene therapy product, ELEVIDYS [1] - The class period for the lawsuit is from June 22, 2023, to June 24, 2025, during which significant safety risks and adverse events associated with ELEVIDYS were allegedly not disclosed [1] - Shareholders are encouraged to register for participation in the class action by the deadline of August 25, 2025, to potentially be appointed as lead plaintiffs [1] Allegations - The complaint alleges that Sarepta Therapeutics made materially false and misleading statements regarding the safety of ELEVIDYS, a gene therapy for Duchenne muscular dystrophy [1] - Specific allegations include failure to disclose significant safety risks, inadequate trial protocols to detect severe side effects, and the potential halting of recruitment and dosing in trials due to adverse events [1] - The misleading statements are said to have artificially inflated the company's stock value, leading to investor losses [2] Next Steps for Shareholders - Shareholders who purchased shares during the specified class period are advised to register for the class action to receive updates and monitor the case [1] - There is no cost or obligation for shareholders to participate in the case [1]

Core Viewpoint - A class action securities lawsuit has been filed against Sarepta Therapeutics, Inc. due to alleged securities fraud affecting investors between June 22, 2023, and June 24, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Sarepta made false statements regarding the safety of its gene therapy ELEVIDYS for Duchenne, which posed significant risks to patients [2] - It is alleged that the trial protocols for ELEVIDYS failed to identify severe side effects, leading to potential halting of recruitment and dosing in trials, increased regulatory scrutiny, and risks to therapy approvals [2] - The defendants are accused of materially misleading investors and lacking a reasonable basis for their positive statements about ELEVIDYS [2] Group 2: Next Steps for Investors - Investors who suffered losses in Sarepta during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4] - The firm has over 70 employees and extensive expertise in complex securities litigation [4]